Defective erythropoiesis in myelodysplastic syndromes
We read with interest the report of Williamson et al describing uncommon cases of red cell aplasia (RCA) in patients with myelodysplastic syndromes (MDS).' The mechanism of RCA in their first three cases was attributed to an intrinsic defect of maturation and proliferation of erythroid precursors occurring as part of the myelodysplastic disorder, whereas in the second three cases a different, and possibly autoimmune aetiology, was suggested. We believe that cytogenetic and molecular study of such unusual cases is important. Most cases of MDS and other malignant haematological disorders are associated with structural chromosomal abnormalities. Cytogenetic study of unusual cases with common features, such as these cases of RCA, might indicate a common chromosomal abnormality which would point to the existence of genes which encode key regulators of erythroid lineage development at or near the junction of the chromosomal aberration. The key regulators of lineage commitment and differentiation in haemopoiesis remain unknown, and an investigative approach through the study of nature's genetic errors might lead to their discovery.
Using such an approach we have recently described a possible association between defective erythropoiesis and an abnormality of chromosome I L2 A case of primary myelofibrosis was identified which showed morphological erythroid aplasia and absent circulating erythroid progenitors. The patient had greatly increased numbers of circulating granulocyte-monocyte progenitor cells (CFU-GM). Co-culture of peripheral blood mononuclear cells with irradiated allogeneic normal bone marrow stroma generated increased numbers of CFU-GM compared with controls but failed to generate erythroid progenitors, providing further evidence for an intrinsic defect in erythropoiesis. Our patient exhibited a previously unreported complex karyotype. Only once previously has the absence of erythroid progenitors in primary myelofibrosis been studied in relation to cytogetic abnormalities, and this case also indicated a complex karyotype which shared with our case a defect on chromosome 11. The abnormality in our case was 1 I q-with the break point at 1 1 q13.
A literature review showed that the protooncogene SEA (S13 avian erythroblastosis oncogene homolog) maps to the 1 1q13 region and we intend to study the possible role ofthis gene at the molecular level. both VL and HIV infection and a greater awareness about this association once the first few cases had been described. In 1990 two independent studies described the features of VL in many cases of HIV.23 More recently, our cooperative multicentre study of 40 patients, including most cases that had appeared in Spain up to the beginning of 1990, has updated that experience.4
Although in some patients VL can be the consequence of reactivated disease, the finding that 92-5% of the patients were intravenous drug misusers suggested that the disease could be transmitted intravenously (which is an occasional route of transmission in immunocompetents). VL can occur at all stages of HIV infection, but 77% of patients were classified as stage IV with CD4 counts below 4 x 109/1, suggesting that it is commoner in the later stages of HIV infection. Most patients present with a clinical picture of "classic" Kala-azar with fever, hepatosplenomegaly, and pancytopenia, but some are asymptomatic and are diagnosed incidentally. In all patients Leishmania amastigotes were demonstrated in the bone marrow smear, and in the liver of 94-5% of the patients who had a biopsy. In four cases L amastigotes were found in normal skin, and were also present in skin lesions of a Kaposi's sarcoma in one case. This is not a surprising finding,as L amastigotes are found in normal skin in immunocompetent patients with VL. VL is an opportunistic infection in HIV seropositive patients that is found increasingly often. It must be suspected and precluded in patients presenting with fever, hepatosplenomegaly, and pancytopenia, and even in less ill patients living in or travelling to endemic areas.
